Evan S Dellon1. 1. Center for Esophageal Diseases and Swallowing, and Center for Gastrointestinal Biology and Disease, Division of Gastroenterology and Hepatology, University of North Carolina School of Medicine, Chapel Hill, NC. Electronic address: edellon@med.unc.edu.
Abstract
OBJECTIVE: To examine costs related to eosinophilic esophagitis (EoE), understand the source of these costs, discuss a possible approach for cost-effective care in EoE, and identify areas for future research in this topic. DATA SOURCES/STUDY SELECTIONS: Narrative review of the literature from 1977 (first description of EoE) to March 2019, focusing on costs and cost-effectiveness analyses in EoE. RESULTS: High costs in EoE can be related to diagnostic delays, requirement for upper endoscopy with biopsy for diagnosis and monitoring of disease activity, expensive medications currently used off-label, increased food costs related to dietary elimination treatment, frequent doctor visits with subspecialists, and complications or disease exacerbations. Provision of cost-effective care in EoE is an understudied area, and a patient-centric approach is key. There are multiple areas in which future research can make an impact. These include determining predictors of treatment response, minimally or noninvasive methods to monitor disease activity, and validation of the use of multidisciplinary care. CONCLUSION: Eosinophilic esophagitis (EoE) is considered to be a rare disease, but the costs of care and burden of disease attributed to EoE are substantial. However, few studies examine either the costs related to EoE or the approach to cost-effective care for the EoE patient. To provide cost-effective care, a patient-centric approach and shared decision-making model are optimal. In addition, a rational strategy for EoE diagnosis and initial treatment, effective maintenance therapy for disease control and ideally to prevent complications, and appropriate long-term monitoring are all required.
OBJECTIVE: To examine costs related to eosinophilic esophagitis (EoE), understand the source of these costs, discuss a possible approach for cost-effective care in EoE, and identify areas for future research in this topic. DATA SOURCES/STUDY SELECTIONS: Narrative review of the literature from 1977 (first description of EoE) to March 2019, focusing on costs and cost-effectiveness analyses in EoE. RESULTS: High costs in EoE can be related to diagnostic delays, requirement for upper endoscopy with biopsy for diagnosis and monitoring of disease activity, expensive medications currently used off-label, increased food costs related to dietary elimination treatment, frequent doctor visits with subspecialists, and complications or disease exacerbations. Provision of cost-effective care in EoE is an understudied area, and a patient-centric approach is key. There are multiple areas in which future research can make an impact. These include determining predictors of treatment response, minimally or noninvasive methods to monitor disease activity, and validation of the use of multidisciplinary care. CONCLUSION:Eosinophilic esophagitis (EoE) is considered to be a rare disease, but the costs of care and burden of disease attributed to EoE are substantial. However, few studies examine either the costs related to EoE or the approach to cost-effective care for the EoE patient. To provide cost-effective care, a patient-centric approach and shared decision-making model are optimal. In addition, a rational strategy for EoE diagnosis and initial treatment, effective maintenance therapy for disease control and ideally to prevent complications, and appropriate long-term monitoring are all required.
Authors: E S Dellon; P D Jones; N B Martin; M Kelly; S C Kim; K L Freeman; E P Dellon; M E Ferris; N J Shaheen Journal: Dis Esophagus Date: 2012-02-06 Impact factor: 3.429
Authors: Ikuo Hirano; Margaret H Collins; Yehudith Assouline-Dayan; Larry Evans; Sandeep Gupta; Alain M Schoepfer; Alex Straumann; Ekaterina Safroneeva; Michael Grimm; Heather Smith; Cindy-Ann Tompkins; Amy Woo; Robert Peach; Paul Frohna; Sheila Gujrathi; Darryl N Penenberg; Caiyan Li; Gregory J Opiteck; Allan Olson; Richard Aranda; Marc E Rothenberg; Evan S Dellon Journal: Gastroenterology Date: 2018-11-02 Impact factor: 22.682
Authors: Anne F Peery; Seth D Crockett; Caitlin C Murphy; Jennifer L Lund; Evan S Dellon; J Lucas Williams; Elizabeth T Jensen; Nicholas J Shaheen; Alfred S Barritt; Sarah R Lieber; Bharati Kochar; Edward L Barnes; Y Claire Fan; Virginia Pate; Joseph Galanko; Todd H Baron; Robert S Sandler Journal: Gastroenterology Date: 2018-10-10 Impact factor: 22.682
Authors: Thomas Greuter; Ekaterina Safroneeva; Christian Bussmann; Luc Biedermann; Stephan R Vavricka; David A Katzka; Alain M Schoepfer; Alex Straumann Journal: Clin Gastroenterol Hepatol Date: 2018-06-11 Impact factor: 11.382
Authors: Sandeep K Gupta; Gary W Falk; Seema S Aceves; Mirna Chehade; Margaret H Collins; Evan S Dellon; Nirmala Gonsalves; Ikuo Hirano; Vincent A Mukkuda; Kathryn A Peterson; Jonathan Spergel; Guang-Yu Yang; Glenn T Furuta; Marc E Rothenberg Journal: Gastroenterology Date: 2018-11-17 Impact factor: 22.682
Authors: W Asher Wolf; Kevin Z Huang; Raquel Durban; Zahra J Iqbal; Benjamin S Robey; Farah J Khalid; Evan S Dellon Journal: Dysphagia Date: 2016-08-09 Impact factor: 3.438
Authors: Ekaterina Safroneeva; Alex Straumann; Michael Coslovsky; Marcel Zwahlen; Claudia E Kuehni; Radoslaw Panczak; Nadine A Haas; Jeffrey A Alexander; Evan S Dellon; Nirmala Gonsalves; Ikuo Hirano; John Leung; Christian Bussmann; Margaret H Collins; Robert O Newbury; Giovanni De Petris; Thomas C Smyrk; John T Woosley; Pu Yan; Guang-Yu Yang; Yvonne Romero; David A Katzka; Glenn T Furuta; Sandeep K Gupta; Seema S Aceves; Mirna Chehade; Jonathan M Spergel; Alain M Schoepfer Journal: Gastroenterology Date: 2015-11-14 Impact factor: 22.682
Authors: Sagar Joshi; Joel H Rubenstein; Evan S Dellon; Nathan Worthing; Zoe Stefanadis; Joy W Chang Journal: Am J Gastroenterol Date: 2021-06-01 Impact factor: 12.045
Authors: Floris M Thunnissen; Bernhard W Schreurs; Carmen S S Latenstein; Marjan J Meinders; Eddy M Adang; Glyn Elwyn; Doeke Boersma; Bas Bosmans; Koop Bosscha; Bastiaan L Ginsel; Eric J Hazebroek; Jeroen J Nieuwenhuis; Maarten Staarink; Dries Verhallen; Marc L Wagener; Femke Atsma; Philip R de Reuver Journal: BMC Med Inform Decis Mak Date: 2021-03-29 Impact factor: 2.796